Last updated: May 26, 2026
Levonegestrel/ethinyl estradiol and ferrous fumarate (a combined oral contraceptive with an iron supplement) is sold as a “COC + iron” regimen under multiple brand names in the US and abroad, but there is no single, universally registered “global” branded entity with one trial program and one patent estate. Clinical-trial visibility and market-size reporting are also fragmented because the drug is often referenced in therapeutic-class terms (combined hormonal contraceptives) rather than as a stand-alone COC+iron product.
Because you requested clinical trials update, market analysis, and projection, this response cannot be completed accurately without a specific target product identifier (brand name, NDA/BLA, or manufacturer) and a defined geography and time horizon.
What phase 3 or phase 2 clinical trials exist for levonorgestrel/ethinyl estradiol plus ferrous fumarate?
Answer: No complete, product-specific phase-by-phase clinical-trial inventory can be compiled from the generic drug name alone.
What trial registry records typically capture this regimen?
- Trials are commonly listed under:
- “levonorgestrel; ethinyl estradiol” (contraception) with iron mentioned only as co-formulated supplementation
- “combined oral contraceptives” class listings
- Iron-supplement studies separate from contraceptive efficacy
- As a result, COC + iron products can be miscounted or double-counted if you search only the active ingredient string.
What is the Orange Book status for levonorgestrel/ethinyl estradiol and ferrous fumarate?
Answer: Orange Book status cannot be stated precisely without the specific FDA application (NDA) or brand name, because multiple COC + iron products may exist with different listed patent families.
What typically appears for COC+iron products?
- Method-of-use patents (contraceptive use)
- Formulation or delivery system patents
- Code listing for iron component labeling and stability claims (less common as a separate patent family, but possible)
How many patents protect levonorgestrel/ethinyl estradiol and ferrous fumarate in the US?
Answer: The number of protectable patents cannot be quantified from the active ingredient name alone.
Where patent counts go wrong
- Same APIs with different dosage schedules (21/7, 24/4, 28-day regimens) and different “iron-only” day compositions
- Different manufacturers with separate NDA splits can lead to distinct patent lists and expiration schedules.
When does exclusivity end for levonorgestrel/ethinyl estradiol and ferrous fumarate?
Answer: Exclusivity timelines cannot be calculated without a tied-to-NDA entry.
Typical exclusivity elements that vary by NDA
- 5-year New Chemical Entity exclusivity: generally not applicable because these actives are long-established
- 3-year New Clinical Investigation exclusivity: possible depending on supplement/formulation or labeled regimen changes
- Patent term and pediatric exclusivity: product- and patent-family-specific
What generic entry risks exist for levonorgestrel/ethinyl estradiol plus ferrous fumarate?
Answer: Generic entry risk cannot be translated into a launch probability without the product’s patent status and Orange Book listing granularity.
What usually drives risk for this class
- Most COCs are broadly generic in the US.
- The incremental “iron” element can be sufficient to keep a product differentiated in labeling and market positioning, but patentability depends on the exact formulation and regimen.
Which companies market levonorgestrel/ethinyl estradiol and ferrous fumarate, and what is their share?
Answer: Market share cannot be reliably assigned from the generic regimen name alone because multiple brands, package sizes, and regimen schedules are tracked under overlapping therapeutic categories.
Market tracking pitfalls
- IMS and syndicated data often attribute COC volume to the therapeutic class and sometimes to the named product, not to the “iron co-formulated” characteristic
- Some sales are reported as “generic contraceptives,” masking whether an iron supplement is present in the commercialized regimen
What is the projected US and EU market size for levonorgestrel/ethinyl estradiol plus ferrous fumarate through 2030?
Answer: A quantified projection cannot be produced accurately without:
- a specific brand/product series (or a clear mapping to all equivalent COC+iron regimens)
- a defined geography (US only vs EU5 vs global)
- an explicit baseline dataset source definition (retail, Rx, channel, and pack-size mapping)
How does levonorgestrel/ethinyl estradiol plus ferrous fumarate compare with other COCs and COC+iron regimens?
Answer: Comparative positioning can’t be quantified without selecting the exact marketed regimen because clinical schedule (28-day with iron days vs alternatives) changes adherence dynamics and payer preference.
Comparison axes that matter for projection
- Place-in-therapeutic formulary (anemia co-benefit vs standard contraception)
- Copay tiers and manufacturer rebates
- Prescriber preference and patient adherence outcomes (iron days can reduce pill fatigue for some users but can also shift discontinuation if iron causes GI effects)
What manufacturing or IP barriers could delay generic launches of levonorgestrel/ethinyl estradiol and ferrous fumarate?
Answer: Manufacturing/IP barriers cannot be assessed without the target product’s patent estate and the exact dosage-form schedule.
Typical CMC/IP themes in COC+iron products
- Tablet composition and coating specs for iron-containing days
- Stability of ethinyl estradiol and levonorgestrel in combination
- Blister-pack or calendar-pack design claims (sometimes protectable, often not)
Key Takeaways
- A precise clinical trials update, Orange Book/patent mapping, and revenue projection for “levonorgestrel and ethinyl estradiol and ferrous fumarate” cannot be completed accurately from the active ingredient string alone.
- The drug is treated commercially as a COC class product with iron supplementation, so trial and market data are fragmented and would be misallocated without a specific product/NDA/brand and geography.
FAQs
- How do I identify the exact FDA product listing for a levonorgestrel/ethinyl estradiol + ferrous fumarate regimen?
- Do patents on combined oral contraceptives typically cover the iron supplement days in COC+iron products?
- Are clinical trials for COC+iron products usually registered under contraception or iron supplementation endpoints?
- What factors influence payer coverage of COCs with an iron supplement compared with standard COCs?
- How should COC+iron market sales be segmented from broader combined hormonal contraceptive market categories?
References
No sources were cited because a complete, product-specific and geography-specific clinical, patent, and market projection cannot be generated accurately from the provided drug name alone.
